Serological Sciences Network
National Cancer Institute's SeroNet explores antibodies to SARS-CoV-2
The Serological Sciences Network (SeroNet) initiative builds testing capacity and investigates immune response to SARS-CoV-2, the coronavirus that causes COVID-19.
Research aims to bolster testing and shed light on course of pandemic
The National Cancer Institute’s (NCI) Serological Sciences Network for COVID-19 is the nation’s largest coordinated effort to quickly increase the nation’s antibody testing capacity and engage the U.S. research community to understand the immune response to COVID-19.
Headquartered at and managed by the Frederick National Laboratory’s Serology Laboratory, SeroNet is a collaboration across 25 biomedical research institutions to enhance understanding of the immune response to the novel coronavirus, SARS-CoV-2.
Collaboration leverages FNL’s serology expertise
The FNL Serology Laboratory is an expansion of the existing HPV Serology Laboratory, which has partnered with the Food and Drug Administration since March to evaluate the sensitivity and specificity of over 80 COVID-19 antibody tests intended for use by the public.